Additionally, bioinformatics analyses have shown that METTL16 is overexpressed in esophageal cancer [57], colorectal cancer (CRC) [58], and predicts poor survival in HCC, CRC, endocrine system tumors, glioma, melanoma, soft-tissue sarcomas, and breast cancer [22,58–63]. Here, METTL16 is linked to breast cancer.